Alligator Bioscience Explores Phase 3 Path for Mitazalimab in Pancreatic Cancer via Unicancer Pact

Alligator Bioscience AB ( (SE:ATORX) ) has issued an update.

Alligator Bioscience has signed a letter of intent with French non-profit cancer research network Unicancer to explore a potential global investigator-sponsored Phase 3 trial of its CD40-targeting antibody mitazalimab in first-line metastatic pancreatic cancer. The collaboration, which remains at an exploratory stage with no development decisions yet taken, could provide a cost-efficient path to late-stage development and bolster Alligator’s position in immuno-oncology if the study proceeds and confirms earlier survival gains.

The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.16 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.

More about Alligator Bioscience AB

Alligator Bioscience is a Swedish biotechnology company focused on developing clinical-stage, tumor-directed antibody drugs targeting the CD40 receptor to enhance T cell priming and counter tumor-specific immunosuppression. Listed on Nasdaq Stockholm, its lead candidate mitazalimab has shown strong survival data in first-line metastatic pancreatic cancer and is ready for Phase 3 development.

Average Trading Volume: 5,284,905

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK83.92M

See more data about ATORX stock on TipRanks’ Stock Analysis page.